Published online before print April 14, 2003, doi: 10.1161/01.CIR.0000065606.63163.B9
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:2493.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
Simvastatin Normalizes Autonomic Neural Control in Experimental Heart Failure
From the Department of Physiology and Biophysics, University of Nebraska Medical Center, Omaha (R.U.P., K.G.C., I.H.Z.), and Department of Pharmacology, Midwestern University, Downers Grove, Ill (J.D.P.).
Correspondence to Irving H. Zucker, PhD, Department of Physiology and Biophysics, University of Nebraska Medical Center, Omaha, NE 68198-4575. E-mail izucker{at}unmc.edu
Background— HMG-CoA reductase inhibitors (statins) have been shown to beneficially affect outcomes in chronic heart failure (CHF). We hypothesized that statins exert effects on autonomic function, as assessed by plasma norepinephrine levels, direct recordings of renal sympathetic nerve activity (RSNA), and baroreflex function.
Methods and Results— Normolipidemic CHF rabbits were treated with simvastatin or vehicle. CHF was induced by continuous ventricular pacing at 320 to 340 bpm for 3 weeks. Two to 3 days after instrumentation of the rabbits with renal nerve electrodes and arterial and venous catheters, blood samples and RSNA recordings were obtained in the conscious state. Baroreflex function was assessed after administration of sodium nitroprusside and phenylephrine. Mean baseline RSNA (±SEM) in normal rabbits was 19.3±3.8%; in CHF rabbits, 39.4±2.9% (P<0.05); in CHF rabbits on low-dose (0.3 mg · kg-1 · d-1) simvastatin, 39.8±8.3% (P<0.05); and in CHF rabbits on high-dose simvastatin (3 mg · kg-1 · d-1), 21.1±4.5% (P=NS). Similar data were observed for plasma norepinephrine. In CHF rabbits treated with 3 mg · kg-1 · d-1 simvastatin, baroreflex regulation of heart rate to transient hypotension with sodium nitroprusside was normalized by 66% compared with CHF controls.
Conclusions— These are the first data showing that non–lipid-lowering statin effects include a normalization of sympathetic outflow and reflex regulation in CHF. The precise neural and cellular pathways involved in these responses need further clarification. This finding may have important implications for the treatment of CHF and progression of the disease process.
Key Words: heart failure • baroreceptors • norepinephrine • HMG-CoA
This article has been cited by other articles:
 |
|
 |
|
  A. Schmechel, M. Grimm, A. El-Armouche, G. Hoppner, A. P. Schwoerer, H. Ehmke, and T. Eschenhagen Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects Cardiovasc Res, April 1, 2009; 82(1): 100 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsuda, Y. Toyohira, S. Ueno, M. Tsutsui, and N. Yanagihara Simvastatin Inhibits Catecholamine Secretion and Synthesis Induced by Acetylcholine via Blocking Na+ and Ca2+ Influx in Bovine Adrenal Medullary Cells J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 130 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Olshansky, H. N. Sabbah, P. J. Hauptman, and W. S. Colucci Parasympathetic Nervous System and Heart Failure: Pathophysiology and Potential Implications for Therapy Circulation, August 19, 2008; 118(8): 863 - 871. [Full Text] [PDF]
|
|
|
|
|
|
L. Gao, W. Wang, and I. H. Zucker Simvastatin Inhibits Central Sympathetic Outflow in Heart Failure by a Nitric-Oxide Synthase Mechanism J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 278 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Mousa, D. Liu, K. G. Cornish, and I. H. Zucker Exercise training enhances baroreflex sensitivity by an angiotensin II-dependent mechanism in chronic heart failure J Appl Physiol, March 1, 2008; 104(3): 616 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 415 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-M. Lee, M.-S. Lin, and N.-C. Chang Effect of pravastatin on sympathetic reinnervation in postinfarcted rats Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3617 - H3626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Di Vanna, A. M. F. W. Braga, M. C. Laterza, L. M. Ueno, M. U. P. B. Rondon, A. C. P. Barretto, H. R. Middlekauff, and C. E. Negrao Blunted muscle vasodilatation during chemoreceptor stimulation in patients with heart failure Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H846 - H852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Khush, D. D. Waters, V. Bittner, P. C. Deedwania, J. J.P. Kastelein, S. J. Lewis, and N. K. Wenger Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study Circulation, February 6, 2007; 115(5): 576 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. Zucker Novel Mechanisms of Sympathetic Regulation in Chronic Heart Failure Hypertension, December 1, 2006; 48(6): 1005 - 1011. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Foody, R. Shah, D. Galusha, F. A. Masoudi, E. P. Havranek, and H. M. Krumholz Statins and Mortality Among Elderly Patients Hospitalized With Heart Failure Circulation, February 28, 2006; 113(8): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ramasubbu and D. L. Mann The Emerging Role of Statins in the Treatment of Heart Failure J. Am. Coll. Cardiol., January 17, 2006; 47(2): 342 - 344. [Full Text] [PDF]
|
|
|
|
|
|
S. Sola, M. Q.S. Mir, S. Lerakis, N. Tandon, and B. V. Khan Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure J. Am. Coll. Cardiol., January 17, 2006; 47(2): 332 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gao, W. Wang, Y.-L. Li, H. D. Schultz, D. Liu, K. G. Cornish, and I. H. Zucker Simvastatin Therapy Normalizes Sympathetic Neural Control in Experimental Heart Failure: Roles of Angiotensin II Type 1 Receptors and NAD(P)H Oxidase Circulation, September 20, 2005; 112(12): 1763 - 1770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Keller and L. Lemberg Statin Therapy in Congestive Heart Failure Am. J. Crit. Care., July 1, 2005; 14(4): 338 - 340. [Full Text] [PDF]
|
|
|
|
|
|
T.-M. Lee, M.-S. Lin, T.-F. Chou, C.-H. Tsai, and N.-C. Chang Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H220 - H227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lorenz, C. Junger, K. Seidl, A. Gitt, S. Schneider, R. Schiele, H. Wienbergen, R. Winkler, M. Gottwik, W. Delius, et al. Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction? Eur. Heart J., June 1, 2005; 26(11): 1078 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schafer, D. Fraccarollo, M. Eigenthaler, P. Tas, A. Firnschild, S. Frantz, G. Ertl, and J. Bauersachs Rosuvastatin Reduces Platelet Activation in Heart Failure: Role of NO Bioavailability Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, F. Angeli, R. Gattobigio, M. Sardone, and C. Porcellati Asymptomatic Left Ventricular Systolic Dysfunction in Essential Hypertension: Prevalence, Determinants, and Prognostic Value Hypertension, March 1, 2005; 45(3): 412 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. O'Neil-Callahan, G. Katsimaglis, M. R. Tepper, J. Ryan, C. Mosby, J. P.A. Ioannidis, and P. G. Danias Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: The Statins for Risk Reduction in Surgery (StaRRS) study J. Am. Coll. Cardiol., February 1, 2005; 45(3): 336 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Ray, Y. Gong, K. Sykora, and J. V. Tu Statin Use and Survival Outcomes in Elderly Patients With Heart Failure Arch Intern Med, January 10, 2005; 165(1): 62 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Joles and H. A. Koomans Causes and Consequences of Increased Sympathetic Activity in Renal Disease Hypertension, April 1, 2004; 43(4): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Koomans, P. J. Blankestijn, and J. A. Joles Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. U. Pliquett, K. G. Cornish, K. P. Patel, H. D. Schultz, J. D. Peuler, and I. H. Zucker Amelioration of depressed cardiopulmonary reflex control of sympathetic nerve activity by short-term exercise training in male rabbits with heart failure J Appl Physiol, November 1, 2003; 95(5): 1883 - 1888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-N. Trochu, S. Mital, X.-p. Zhang, X. Xu, M. Ochoa, J. K Liao, F. A Recchia, and T. H Hintze Preservation of NO production by statins in the treatment of heart failure Cardiovasc Res, November 1, 2003; 60(2): 250 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. U. Pliquett, K. G. Cornish, and I. H. Zucker Statin therapy restores sympathovagal balance in experimental heart failure J Appl Physiol, August 1, 2003; 95(2): 700 - 704. [Abstract] [Full Text] [PDF]
|
|